APPLICATIONS PUBLISHED 7 JANUARY 2004
Published: 1-Jun-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Method for producing an active ingredient concentrate, and an active ingredient concentrate
Aquanova German Solubilisate Technologies 1377273*
Drug delivery system for hydrophobic drugs
QLT 1377274*
Vaccine for modulating between T1 and T2 immune responses
Biomira 1377275*
Timed pulse release compsn
Sun Pharmaceutical Industries 1377276*
Pharmaceutical compsns comprising pravastatin for reducing LDL cholesterol levels
Bristol-Myer s Squibb 1377277*
Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
Ferring BV 1377278*
Inhibition of ERK to reduce or prevent tolerance to and dependence on opioid analgesics
Board of Regents, The University of Texas System 1377279*
Buling agents as satiety agents
Dansico USA 1377280*
Taurine compounds
Rhode Island Hospital 1377281*
Aryl-N-cyanoguanidines and methods related thereto
Mitokor 1377282*
Compounds of the formula R1-X-Y-Z-NR2R3 as ABCA-1 elevating agents against coronary artery disease or atherosclerosis
CV Therapeutics 1377283*
Controlled release arginine formulations
Angiogenix 1377284*
Pharmaceutical compsn comprising ibuprofen and prochlorperazine
The Boots Company 1377285*
Treatment of schizophrenia
Ziegler, Randy 1377286*
Proanthocyanidins for the treatment of amyloid and alpha-synclein diseases
Proteotech 1377287*
2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
Bristol-Myers Squibb 1377288*
Heterocyclic compounds for therapeutic use
JB Chemicals & Pharmaceuticals 1377289*
Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
Chugai Seiyaku KK 1377290*
1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives and the therapeutic use thereof
Protagen 1377291*
Compsn for the treatment of night sight problems (halo, coma and glare) comprising aceclidine
Randazzo, Alessandro 1377292*
Aryl and biaryl piperidines used as MCH antagonists
Pharmacopeia 1377293*
Use of neuroactive substances for the treatment of Parkinson's disease and pharmaceutical combination
Dawirs, Ralph 1377294*
Carboxamide derivatives as therapeutic agents
Transtech Pharma 1377295*
Antiviral method of use
Eli Lilly & Co 1377296*
Degradation-resistant glucocorticosteroid formulations
Ivax Research 1377297*
Combined method for treating hormono-dependent disorders
Pharmacia Italia; Pharmacia & Upjohn 1377298*
Transcutaneous immunostimulation
Iomai Corp 1377299*
Zinc ionophores as antistress agents
Fliss, Henry 1377300*
Normalisation of degenerative T-cell responsiveness through manipulation of thymic regeneration
Monash University 1377301*
Compsns and methods for protecting tissues and cells from damage, and for repairing damaged tissues
Phylogix 1377302*
Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation
Universitair Medisch Centrum Utrecht 1377303*
A novel TRP2 isoform containing HLA-A2 restricted cytotoxic T lymphocyte epitopes
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 1377304*
Tryptophanyl-TRNA synthetase derived polypeptides useful for the regulation of angiogenesis
The Scripps Research Institute 1377305*
Serum albumin binding moieties
Dyax Corp 1377306*
Anti-GPE antibodies, their uses, and analytical methods for GPE
Neuronz; Freyburg, Derek 1377307*
Use of the protein UK114 or fragments thereof for the treatment and prevention of the endotoxic shock
Zetesis 1377308*
Combinations of heparin cofactor II agonist and platelet IIB/IIIA antagonist, and uses thereof
IntimaX 1377309*
Modulation of smooth muscle cell proliferation by VEGF-X or antagonists thereof
Janssen Pharmaceutica 1377310*
Treatment of neuropathologies associated with expression of TNF-alpha
Medical Research Council 1377311*
Anthrax lethal factor inhibits tumour growth and angiogenesis
Van Andel Institute 1377312*
Enzymes combination coadjuvating in the interferon therapy
Medeastea Research & Production 1377313*
Monoclonal antibodies to the CLFA protein and method of use in treating or preventing infections
Inhibitex 1377314*
Pharmaceutical compsns
Novartis 1377315*
Pharmaceutical compsn based on macrolides for topical application in ophthalmology
Laboratoires THEA 1377316*
Multiple epitopes connected by a carrier
University of Medicine and Dentistry of New Jersey 1377317*
Pregablin lactose conjugates
Warner-Lambert 1377318*
Fusion proteins
Bioaxone Therapeutique 1377319*
Polynucleotide binding complexes comprising sterols and saponins
Nordic Vaccine Technology 1377320*
Labelled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
Bristol-Myers Squibb 1377321*
